Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Can-Fite Biopharma Ltd (CANF : AMEX)

• Company Description    Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company's lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate is being developed for the treatment of liver diseases and its CF602 drug is being developed for the treatment of inflammation and sexual dysfunction. Can Fite Biopharma Ltd. is based in Petach Tikva, Israel. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $1.03 Daily Weekly Monthly 20 Day Moving Average: 139,315 shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 1.11 52 Week High: $4.69 52 Week Low: $0.98 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.17% -7.76% 12 Week -13.75% -27.45% Year To Date -36.31% -40.35%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 26 BEN GURION STREET - RAMAT GAN,L3 5257346 ISR ph: 972-3924-1114 fax: 972-3924-9378 info@canfite.co.il http://www.canfite.com

• General Corporate Information    Officers Motti Farbstein - Chief Executive; Financial and Operating Officer Pnina Fishman - Chairman of the Board Sari Fishman - Vice President Guy Regev - Director Abraham Sartani - Director Peer Information Can-Fite Biopharma Ltd (GSAC) Can-Fite Biopharma Ltd (CASI) Can-Fite Biopharma Ltd (ALCD.) Can-Fite Biopharma Ltd (OMNN) Can-Fite Biopharma Ltd (CGPI.) Can-Fite Biopharma Ltd (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 13471N300 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: Most Recent Split Date: 1.00 (0.10:1) Beta: 1.11 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.67 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 4.38 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 4.38 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -1,169.14 Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - 1.54 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©